Want to see GB:4BB full AI Analyst Report?
Top Page
4basebio UK Societas
(LSE:4BB)
Select Model
Select Model
Rating:47Neutral
Price Target:
463.00 p
▼(-11.81% Downside)
Action:Reiterated
Date:08/26/26
The score is held down primarily by weak financial performance (widening losses, persistent and rising cash burn, and a weaker 2025 balance sheet with higher leverage). Technicals also point to a clear downtrend despite oversold signals. Offsetting these negatives, corporate events are supportive (Genezen collaboration and governance/incentive actions), but valuation is constrained by a loss-making profile and no stated dividend.
Positive Factors
Synthetic DNA Platform
The proprietary cell-free DNA platform targets critical inputs for advanced therapeutics and may offer developers scalable, application-specific materials. Its relevance across several genetic-medicine applications supports potential long-term market breadth and differentiation.
Negative Factors
Persistent Loss-Making Operations
The company has not yet converted its technology into sustainable operating profitability. Declining recent revenue and expanding losses indicate that operating costs still overwhelm gross profit, creating continued dependence on successful commercial scaling or cost reductions.
Read all positive and negative factors
Positive Factors
Negative Factors
Synthetic DNA Platform
The proprietary cell-free DNA platform targets critical inputs for advanced therapeutics and may offer developers scalable, application-specific materials. Its relevance across several genetic-medicine applications supports potential long-term market breadth and differentiation.
Read all positive factors
4basebio UK Societas (4BB) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£72.78M
Dividend YieldN/A
Average Volume (3M)999.00
Price to Earnings (P/E)―
Beta (1Y)-0.19
Revenue Growth81.46%
EPS Growth-15.88%
CountryUK
Employees140
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.09
Shares Outstanding15,538,518
10 Day Avg. Volume230
30 Day Avg. Volume999
Financial Highlights & Ratios
PEG Ratio-0.35
Price to Book (P/B)9.43
Price to Sales (P/S)56.33
P/FCF Ratio-6.27
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
£1,400.00Price Target Upside166.67% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1
Revenue Forecast (FY)£2.60M
4basebio UK Societas Business Overview & Revenue Model
Company Description
4basebio PLC, an enterprise established in 2020 and situated in Cambridge, United Kingdom, is dedicated to the entire process, from conception to delivery, of synthetic DNA and RNA products. The company also provides advanced non-viral vector solu...
How the Company Makes Money
null...
4basebio UK Societas Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
34
Negative
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 1.69M | 933.00K | 506.00K | 268.00K | 338.00K |
| Gross Profit | 548.00K | 630.00K | 340.00K | 239.00K | 269.00K |
| EBITDA | -15.58M | -10.97M | -7.34M | -5.41M | -3.21M |
| Net Income | -16.91M | -12.33M | -7.67M | -5.15M | -3.23M |
Balance Sheet | |||||
| Total Assets | 29.55M | 44.73M | 11.92M | 11.69M | 14.70M |
| Cash, Cash Equivalents and Short-Term Investments | 17.80M | 34.60M | 3.07M | 4.35M | 9.59M |
| Total Debt | 16.50M | 15.22M | 10.46M | 3.35M | 1.76M |
| Total Liabilities | 19.44M | 18.35M | 12.41M | 4.57M | 3.01M |
| Stockholders Equity | 10.11M | 26.38M | -492.00K | 7.12M | 11.70M |
Cash Flow | |||||
| Free Cash Flow | -15.21M | -12.31M | -7.67M | -6.64M | -4.25M |
| Operating Cash Flow | -14.75M | -10.74M | -6.18M | -4.70M | -2.74M |
| Investing Cash Flow | -1.64M | -1.57M | -1.49M | -1.94M | -1.51M |
| Financing Cash Flow | -369.00K | 43.87M | 6.42M | 1.24M | -467.00K |
4basebio UK Societas Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | £91.44M | 12.32 | 65.83% | 9.84% | -8.21% | -5.27% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £72.78M | -4.36 | -116.21% | ― | 81.46% | -15.88% | |
47 Neutral | £325.54M | -7.43 | -2929.47% | ― | ― | ― | |
46 Neutral | £13.01M | -3.25 | -135.35% | ― | 13.42% | 65.63% | |
44 Neutral | £14.08M | -7.81 | -210.32% | ― | -11.43% | 23.40% | |
38 Underperform | £5.26M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:4BB
4basebio UK Societas
475.00
-410.00
-46.33%
GB:AVCT
Avacta Group plc
69.20
14.20
25.82%
GB:BVXP
Bioventix
1,750.00
-592.34
-25.29%
GB:OBD
Oxford BioDynamics
0.12
-0.36
-75.63%
GB:FAB
Fusion Antibodies Plc
11.25
-3.50
-23.73%
GB:APTA
Aptamer Group Plc
0.33
-0.68
-67.50%
4basebio UK Societas Corporate Events
Business Operations and Strategy
4basebio Strikes Genezen Pact to Advance Synthetic DNA for Viral Vector Manufacturing
Positive
Aug 26, 2026
4basebio PLC, a UK-listed biotech focused on synthetic, cell-free DNA and mRNA for advanced gene and cell therapies, develops GMP-grade DNA constructs tailored to applications such as viral vectors, genome editing, and DNA vaccines. The company po...
Business Operations and StrategyExecutive/Board Changes
4basebio awards new management share options to support long-term growth
Positive
Jul 22, 2026
4basebio PLC has granted a total of 684,872 share options to senior executives and a PDMR as part of its long-term incentive arrangements. The bulk of the options, issued to CEO Dr. Amy Walker, Executive Chair Dr. Manja Boerman and non-executive d...
Business Operations and StrategyExecutive/Board Changes
4basebio strengthens board with deep tech investor Cornel Chiriac
Positive
Jul 8, 2026
4basebio PLC has appointed Mr. Cornel Chiriac as a non-executive director with immediate effect, adding seasoned investment and deep tech venture expertise to its board. Chiriac, an investment director at MG Investments’ Crossover Fund, brin...
Business Operations and StrategyShareholder Meetings
4basebio Secures AGM Backing and Awards New Employee Share Options
Positive
Jun 30, 2026
4basebio PLC reported that all resolutions were approved at its Annual General Meeting held on 30 June 2026, confirming shareholder support for the board’s proposals. The meeting outcome reinforces governance stability as the company advance...
Business Operations and Strategy
4basebio Sets Investor Presentation as It Advances Synthetic DNA Platform
Positive
Jun 16, 2026
4basebio PLC, a Cambridge-based biotechnology company specialising in enzymatically produced synthetic DNA and mRNA for advanced genetic medicines, leverages its proprietary platform to deliver GMP-grade, application-specific constructs for gene t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.